BACKGROUND: The lysine salt of bendazac is a non-steroidal anti-inflammatory agent, and it is marketed exclusively for the treatment of cataracts. We report two cases of possible hepatotoxicity due to the use of bendazac lysine. METHODS: Laboratory tests, serologic tests, abdominal sonography and scan were performed to study liver disease. RESULTS: Reversible increases of the hepatic enzymes were found in both cases. Anemia was also found in one of the cases (case 1). CONCLUSIONS: Abnormal liver test results could be related to a possible liver injury attributed to the use of bendazac lysine.
BACKGROUND: The lysine salt of bendazac is a non-steroidal anti-inflammatory agent, and it is marketed exclusively for the treatment of cataracts. We report two cases of possible hepatotoxicity due to the use of bendazac lysine. METHODS: Laboratory tests, serologic tests, abdominal sonography and scan were performed to study liver disease. RESULTS: Reversible increases of the hepatic enzymes were found in both cases. Anemia was also found in one of the cases (case 1). CONCLUSIONS: Abnormal liver test results could be related to a possible liver injury attributed to the use of bendazac lysine.
Authors: Giovanni Polimeni; Francesco Salvo; Paola Cutroneo; Ilaria Morreale; Achille Patrizio Caputi Journal: Drug Saf Date: 2006 Impact factor: 5.606